Poor medication adherence in clinical trials: Consequences and solutions

Nature Reviews Drug Discovery

Volumn 16, Issue 3, 2017, Pages 149-150

  Breckenridge, Alasdair ^a   Aronson, Jeffrey K ^b   Blaschke, Terrence F ^c   Hartman, Dan ^d   Peck, Carl C ^e   Vrijens, Bernard ^f  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BILL AND MELINDA GATES FOUNDATION   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Westrock Healthcare   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; EMTRICITABINE; TENOFOVIR DISOPROXIL;

AMBULATORY CARE; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG RESISTANCE; DRUG TREATMENT FAILURE; HUMAN; INTENTION TO TREAT ANALYSIS; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PRODUCT DEVELOPMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RARE DISEASE; REVIEW; RISK FACTOR; PROCEDURES; STANDARDS; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; HUMANS; MEDICATION ADHERENCE; TREATMENT OUTCOME;

EID: 85011564414     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd.2017.1     Document Type: Review

References (5)

1. Marrazzo J. M. et al. Tenofovir-based pre-exposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 372, 509-518 (2015).
2. Blaschke T. F. et al. Adherence to medications. Insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu. Rev. Pharmacol. Toxicol. 52, 275-301 (2012).
3. Bhatia S. et al. Non adherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukaemia. J. Clin. Oncol. 17, 2094-2101 (2012).
4. Marin D. et al. Adherence is a critical factor for achieving molecular responses in patients with chronic myeloid leukaemia who achieve complete cytogenic responses on imatinib. J. Clin. Oncol. 28, 2381-2388 (2010).
5. Corral G. et al. Adherence with antihypertensive drug therapy and the risk of heart failure in clinical practice. Hypertension 66, 742-749 (2015).